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Background: Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis is a rare tubulopathy leading to
renal calcification and progressive renal failure.
Case presentation: We report a consanguineous Arab family (of Qatari origin) with 7 affected siblings with variable
phenotypes including hypomagnesaemia, hypercalciuria, nephrocalcinosis and renal stones. Presenting features
included haematuria and recurrent urinary tract infections. As the biochemical and clinical phenotypes of this family
resembled familial hypomagnesaemia with hypercalciuria and nephrocalcinosis, we performed genetic investigation
in order to provide a precise molecular diagnosis. We screened all coding regions of the CLDN16 gene and
identified a novel mutation (c.G647A, p.R216H) which was found homozygously in the six severely affected cases,
who manifested significant nephrocalcinosis, often nephrolithiasis and sometimes reduced GFR. Parents were both
heterozygous for the mutation and, together with children carrying the mutation in its heterozygous state,
exhibited mild or no biochemical phenotypes.
Conclusion: Mutations in CLDN16 underlie familial hypomagnesaemia with hypercalciuria and nephrocalcinosis but
remain a rare cause of nephrocalcinosis and nephrolithiasis. Management includes reduction of hypercalciuria with
thiazide diuretics, correction of serum magnesium and close monitoring of renal function given the significant risk
of end stage renal failure with this inherited form of nephrocalcinosis.
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Renal tubulopathies may present to a wide spectrum of
clinicians with a variety of clinical, biochemical and radio-
logical features. Renal tubular wasting of calcium and mag-
nesium underlie the autosomal recessive disorder known as
familial hypomagnesaemia with hypercalciuria and nephro-
calcinosis (FHHNC) [1]. The clinical presentation often
relates to the complications of severe hypercalciuria and
nephrocalcinosis and may include haematuria, urinary
tract infections and renal colic/calculi. The condition
leads to progressive renal failure, often within the first
two decades of life. Compound heterozygous or homo-
zygous mutations in CLDN16, encoding a tight junction* Correspondence: john.sayer@ncl.ac.uk
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reproduction in any medium, provided the orprotein expressed in the thick ascending limb of the
loop of Henle, underlie this disorder.
We report a large consanguineous family who presented
with a variety of clinical and biochemical features suggest-
ive of familial hypomagnesaemia with hypercalciuria and
nephrocalcinosis (FHHNC) in whom we have identified a
novel homozygous CLDN16 mutation.
Case presentation
A large Qatari family (Figure 1A) presented with a variety
of clinical features suggestive of an inherited tubulopathy.
Clinical presentation of disease, even within the same
family, was within a wide age range (Table 1).
The index case (II:1) presented 20 years of age with
macroscopic haematuria. He had a past medical history
of recurrent attacks of left loin pain typical of renal colic
and was known to have renal stone disease and recurrenttd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Molecular genetic investigation of the family. (A) Pedigree diagram of consanguineous multiplex family with homozygous and
heterozygously affected members with Familial Hypomagnesaemia with Hypercalciuria and Nephrocalcinosis and CLDN16 mutations. Circles
females, squares males, shaded = affected, half shaded = heterozygous carrier. (B) Mutational analysis and segregation demonstrates a c. G647A
nucleotide substitution in exon 4 of CLDN16 leading to a missense change p. R216H. Amino acids and position are annotated below the
chromatograms. (C) Claudin-16 protein (alias paracellin) model deduced from hydrophobicity plots and drawn using www.sacs.ucsf.edu/TOPO2.
The mutated R216 in the second extracellular loop is annotated. (D) R216 residue (arrowed) is highly conserved from Human to Xenopus.
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I:1 45 F - 2.43 0.8 N/A Yes N/A No No - Het
I:2 48 M - 2.40 N/A N/A No N/A No No - Het
II:1 26 M Macroscopic
haematuria
20 years 2.11 0.52 35.1 Yes Yes Yes Yes 48 Homo
II:2 25 M Recurrent UTI,
microscopic
haematuria
20 years 2.10 0.60 N/A Yes Yes Yes No 37 Homo
II:3 24 M Loin pain,
passed a stone
17 years 2.13 0.59 29.4 Yes N/A Yes Yes 67 Homo
II:4 23 M Recurrent UTI,
microscopic
haematuria
17 years 2.25 0.85 21.3 No N/A No No 126 Het
II:6 22 M Recurrent UTI,
microscopic
haematuria
16 years 2.08 0.45 N/A No Yes Yes No 37 Homo
II:8 12 F Loin pain 7 years 2.09 0.47 35.2 No Yes Yes No 36 Homo
II:11 3 F Haematuria 17 months 2.40 0.76 61.0 No N/A Yes No N/A Homo
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normal blood pressure and a BMI of 28.5 Kg/m2.
Biochemical investigations revealed hypercalciuria
(24 h urine calcium 9.83 mmol/day; reference range
2.5-8.5), hypomagnesaemia (0.52 mmol/l) and hypocal-
caemia (2.11 mmol/l). Serum parathyroid hormone was
raised at 16.96 pmol/L (reference range 1.3-6) in the
context of low total vitamin D levels (39.9 nmol/l; refer-
ence range 75-200). There was also profound hypoci-
traturia (21 mg/day, reference range 290-888). Serum
creatinine was elevated at 160 umol/l consistent with
CKD stage 3 (Table 1).
A renal ultrasound demonstrated multiple fine echo-
genic cortical calcifications in both kidneys consistent
with nephrocalcinosis and parenchymal renal calculi. The
right kidney measured 9.8 cm in length and the left kidney
measured 10.0 cm. No cystic change was noted within
the kidneys. An abdominal CT confirmed nephrocalci-
nosis (Figure 2A). Isotope imaging of the neck showed
no evidence of a parathyroid adenoma.
The patient was managed with an increase in fluids, to
reduce risk of stone formation and the addition of mag-
nesium supplements and a thiazide diuretic in the form
of hydrochlorothiazide 25 mg daily.
A second family member (II:8) presented at 7 years of
age with right sided loin pain. Biochemical investigations
also revealed hypocalcaemia (2.09 mmol/l) and hypo-
magnesaemia (0.56 mmol/l) with a raised PTH 11 pmol/l
in the context of a low total vitamin D level (36 nmol/l).Figure 2 Imaging of the renal tract in affected members. A. CT scan sh
showing bilateral nephrocalcinosis in II:3, aged 22 years. C. CT scan showin
demonstrating nephrocalcinosis in II:11, aged 3 years.There was no evidence of hypercalciuria or hypermag-
nesuria (Table 1). Renal imaging (USS and CT scan)
demonstrated nephrocalcinosis with bilateral symmet-
rical diffuse calyceal calcifications (Figure 2C). The child
was similarly treated with magnesium supplementation
and thiazide diuretics.
The discovery of these two cases of hypocalcaemia
and hypomagnesaemia with hypercalciuria and nephro-
calcinosis within the same family prompted a review of
other affected family members, who had presented inde-
pendently to other physicians and their parents. The
clinical findings are detailed in Table 1 and renal im-
aging is shown in Figure 2. Family member II:11 is note-
worthy given the early presentation at 17 months of age,
following a urinary tract infection. USS of the renal tract,
even at this young age, demonstrated nephrocalcinosis
(Figure 2D).
Genetic investigations
Following informed consent from all adult patients/
relatives and from the parents or guardians of the pa-
tients who were under the age of 18, DNA samples were
obtained and all coding regions of the CLDN16 gene
were amplified and sequenced directly using Sanger
sequencing.
We identified a novel missense mutation in exon 4 of
the CLDN16 gene (c.G647A, p.R216H), located in the
second extracellular loop (Figure 1B, C). In silico predic-
tion tools predict that the mutation is pathogenic. Theowing bilateral nephrocalcinosis in II:1, aged 26 years. B. CT scan
g bilateral nephrocalcinosis in II:8, aged 12 years. D. Renal USS
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Exome Variant Server databases. The Arginine residue
is highly conserved (Figure 1D). Interestingly, a R216C
mutation, affecting the same residue, has been previ-
ously reported [2,3]. This R216C sequence variant was
not observed in 100 European and 50 Japanese control
alleles [2,3].
Mutations in CLDN16 (alias PCLN1) cause the auto-
somal recessive condition familial hypomagnesaemia with
hypercalciuria and nephrocalcinosis (FHHNC) [1]. The
phenotype includes renal magnesium and calcium wast-
ing secondary to defects in the thick ascending limb re-
absorption of calcium and magnesium, which leak through
defective tight junctions owing to mutations in CLDN16
encoding claudin-16. The expression of claudin-16 is
limited to the tight junctions of renal epithelial cells of
the thick ascending limb of the loop of Henle [4]. The
clinical presentation may be in childhood or adoles-
cence with symptomatic hypocalcaemia [3,5-8].
As seen in this family, nephrocalcinosis and recurrent
nephrolithiasis are also seen. Nephrocalcinosis may con-
tribute to a renal tubular acidification defect and to the
inability to concentrate urine and hypokalaemia may
also be a feature. Our family was typical of many cases
of FHHNC, with affected members presenting with re-
current urinary tract infections. Other features can in-
clude polyuria/polydipsia, rickets, haematuria, muscular
tetany, seizures, failure to thrive, vomiting, and abdom-
inal pain [9,10]. Additional biochemical findings can in-
clude hypocitraturia [11], increased parathyroid hormone
(PTH) levels (independent of GFR) [5], and hyperuricae-
mia. Worryingly, FHHNC is often complicated by pro-
gressive renal failure which occurs during childhood or
adolescence. Within this family there was a variable loss
of renal function, with some family members with sig-
nificant renal impairment at a young age (Table 1).
The phenotype of heterozygous carriers of CLDN16
mutations is not totally benign. Hypercalciuria, as seen
in this family, and even nephrolithiasis may be seen in
heterozygous “carriers” of mutations [5,10].
Mutations in the CLDN19 gene (encoding a related
tight junction protein, Claudin-19) can produce the same
biochemical phenotype as CLDN16 mutations [3]. How-
ever, patients with CLDN19 mutations had additional
phenotypes including eye involvement and severe visual
impairment.
Mutational analysis has allowed the identification
of ~50 different mutations of CLDN16. In one study
of 32 patients, nearly half had a L151F missense mu-
tation. This mutational hot spot was proposed to be
due to a founder effect (Germany and Eastern European
countries) [10]. The R216H mutation, affecting the second
extracellular loop, found in this family is novel. The
extracellular loops are important for interactions betweenclaudin molecules of neighbouring cells [12]. Mutations
affecting the same amino acid have been described pre-
viously. An R216C mutation has been described in a
heterozygous state, in combination with a R149Q mis-
sense mutation in a Japanese child presenting at 5 years
of age with haematuria, hypercalciuria, and nephrocalci-
nosis [2,3]. In addition, a R216T mutation has also been
described [4,13]. In functional studies the R216T muta-
tion was shown to mis-traffic to the tight-junction [13]
although was seen to correctly localise to the tight junc-
tion, with a magnesium transport defect, by other inves-
tigators [4].
Other inherited disorders that may present in child-
hood with hypomagnesaemia include Gitelman’s syn-
drome [14], familial hypomagnesaemia with secondary
hypocalcaemia (HSH) [15] and autosomal dominant
hypomagnesaemia [16]. Gitelman’s syndrome is renal
salt-wasting alkalosis characterised by a hypokalaemic
metabolic alkalosis [14]. Gitelman’s patients typically have
hypocalciuria and do not exhibit nephrocalcinosis [17].
Mutations in SLC12A3 encoding the thiazide-sensitive
sodium-chloride co-transporter underlie this disease [14].
Familial hypomagnesaemia with secondary hypocalcaemia
(HSH) is a rare autosomal recessive disease caused by
mutations in TRPM6 an apical magnesium uptake chan-
nel in the intestine and distal convoluted tubule of the
kidney [18]. The biochemical phenotype usually reveals
an extremely low serum magnesium. There is secondary
low serum calcium levels, thought to be due to an im-
paired synthesis and/or release of PTH. Again, nephro-
calcinosis would not be an expected feature of patients
with TRPM6 mutations. Autosomal dominant hypomag-
nesaemia is a renal magnesium wasting tubulopathy. A
mild hypomagnesaemia occurs and an associated hypo-
calciuria. Mutations in the FXYD2 gene are responsible
for this disorder [16].
Another condition that may cause diagnostic confu-
sion with FHHNC is autosomal dominant hypocalcaemia
(ADH) secondary to activating mutations of the calcium-
sensing receptor that lead to hypocalcaemia with hyper-
calciuria [19]. Hypomagnesaemia can be a feature of this
condition and typically serum PTH is in the low-normal
range. Here the inheritance pattern is autosomal domin-
ant and the majority of patients are asymptomatic and are
diagnosed as adults when hypocalcaemia is noted as an
incidental finding. Some patients exhibit a salt wasting
phenotype with hypokalaemia, mimicking Bartter’s syn-
drome [20]. In ADH, vitamin D and calcium supple-
mentation worsen the hypercalciuria, and may lead to
increased nephrocalcinosis and calcium stone forma-
tion. Genetic testing of the CASR gene allows a molecu-
lar diagnosis to be made [21].
For the medical management of cases of FHHNC, atten-
tion should be given to the management of the biochemical
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the calcium excretion in patients with FHHNC [22] and
magnesium supplementation should be given. In addition,
Vitamin D and calcium supplementation may be required.
There was evidence of vitamin D deficiency in the family
we describe. Limited sunlight exposure and poor oral in-
take of vitamin D are common risk factors for vitamin D
deficiency in the Middle East [23]. The dramatic loss of
renal function in patients with CLDN16 mutations is a
noteworthy and worrying feature, and the aetiology of
which is currently unclear [3]. It can be speculated
that the dramatic nephrocalcinosis is contributory, yet
there are other renal disorders with nephrocalcinosis
that do not show similar rates of decline in renal func-
tion [24]. Strategies to measure and optimise renal
function are important. Urinary tract infections and
obstructive calculi should be treated promptly to pre-
vent ascending infections, obstruction and further renal
insults. As expected from an inherited tubulopathy, fol-
lowing renal transplantation, magnesium and calcium
regulation normalize, indicating that FHHNC patients
are ideal candidates for renal transplantation [5].
Conclusions
In summary, in we have made a molecular genetic diag-
nosis of a CLDN16 mutation in a large consanguineous
family with nephrocalcinosis, renal stones and renal im-
pairment. Age and clinical features at presentation can
be very variable, even from within the same family. A
molecular genetic diagnosis enables a screen of other
family members at risk of disease and allows management
of urinary electrolyte abnormalities to prevent further de-
terioration in renal function and renal stone formation.
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